Millipore Sigma Vibrant Logo

530070 Pristimerin - CAS 1258-84-0 - Calbiochem

A cell-permeable plant dienone-phenolic triterpenoid, naturally isolated from tripterygium wilfordii.

Pristimerin - CAS 1258-84-0 - Calbiochem MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.

同义词: Monoacylglycerol Lipase Inhibitor II, Proteasome Inhibitor XV, NF-κB Activation Inhibitor IX, MAGL Inhibitor II

View Products on Sigmaaldrich.com
530070
查看价格及供货情况

概述

Replacement Information

重要规格表

CAS #Empirical Formula
1258-84-0C₃₀H₄₀O₄

价格及供货情况

产品目录编号 库存情况包装 数量 / 包装 价格 数量
530070-5MGCN
正在查询供货情况......
—
目前缺货 目前缺货
有货 
停产
少量现货
供货情况有待确认
    其余：另行通知
      其余：另行通知
      另行通知
      联系客户服务
      Contact Customer Service

      		 塑胶安瓿;塑胶针药瓶 5 mg
      正在检索价格......
      无法检索价格。
      最小订购数量为倍数
      Maximum Quantity is
      以订单确认为准 更多信息
      您节约了 ()。
       
      —
      Request Pricing
      		 —
      Description
      OverviewA cell-permeable plant dienone-phenolic triterpenoid, naturally isolated from tripterygium wilfordii, whose inhibitory activities against proteasome chymotrypsin subunit (IC50 = 2.2 and 3.0 µM against purified rabbit 20S and human 26S proteasome, respectively) and cellular NF-κB pathway/IKK activation most likely account for its reported anticancer efficacy both in vitro (IC50 ≤610 nM in A549, K562, KBM5, MCF-7, MDA-MB-231, HepG2, and primary human leukemia cell cultures) and in mice in vivo (1 to 2.5 mg/kg/day, s.c.), including imatinib/STI571-resistant cancer cells harboring Bcr-Abl T315I mutation. Also reported to inhibit the activity of monoacylglycerol lipase (MGL), the enzyme that hydrolyzes and deactivates the cannabionoid receptor ligand 2-Arachidonoyl-sn-glycerol (2-AG), in a reversible manner with high potency (IC50 = 93 nM).
      Catalogue Number530070
      Brand Family Calbiochem®
      SynonymsMonoacylglycerol Lipase Inhibitor II, Proteasome Inhibitor XV, NF-κB Activation Inhibitor IX, MAGL Inhibitor II
      References
      ReferencesLu, Z., et al. 2010. Mol. Cancer 9, 112.
      King, A.R., et al. 2009. Chem. Biol. 16, 1045.
      Tiedemann, R.E., et al. 2009. Blood 113, 4027.
      Yang, H., et al. 2008. J. Cell. Biochem. 103, 234.
      Wu, C.C., et al. 2005. Mol. Cancer Ther. 4, 1277.
      Product Information
      CAS number1258-84-0
      FormRed solid
      Hill FormulaC₃₀H₄₀O₄
      Chemical formulaC₃₀H₄₀O₄
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Purity≥95% by HPLC
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      S PhraseS: 20-24/25-36/37/39

      When using do not eat or drink.
      Avoid contact with skin and eyes.
      Wear suitable protective clothing, gloves and eye/face protection.
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Standard Handling
      Storage +2°C to +8°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      产品目录编号 GTIN
      530070-5MGCN 04055977269352

      Documentation

      Pristimerin - CAS 1258-84-0 - Calbiochem MSDS

      职位

      物料安全数据表 (MSDS) 

      Pristimerin - CAS 1258-84-0 - Calbiochem 分析证书

      标题批号
      530070

      参考

      参考信息概述
      Lu, Z., et al. 2010. Mol. Cancer 9, 112.
      King, A.R., et al. 2009. Chem. Biol. 16, 1045.
      Tiedemann, R.E., et al. 2009. Blood 113, 4027.
      Yang, H., et al. 2008. J. Cell. Biochem. 103, 234.
      Wu, C.C., et al. 2005. Mol. Cancer Ther. 4, 1277.
      数据表

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision09-August-2010 RFH
      SynonymsMonoacylglycerol Lipase Inhibitor II, Proteasome Inhibitor XV, NF-κB Activation Inhibitor IX, MAGL Inhibitor II
      DescriptionA cell-permeable plant dienone-phenolic triterpenoid, naturally isolated from tripterygium wilfordii, whose inhibitory activities against proteasome chymotrypsin subunit (IC50 = 2.2 and 3.0 µM against purified rabbit 20S and human 26S proteasome, respectively) and cellular NF-κB pathway/IKK activation most likely account for its reported anticancer efficacy both in vitro (IC50 ≤610 nM in A549, K562, KBM5, MCF-7, MDA-MB-231, HepG2, and primary human leukemia cell cultures) and in mice in vivo (1 to 2.5 mg/kg/day, s.c.), including imatinib/STI571-resistant cancer cells harboring Bcr-Abl T315I mutation. Also reported to inhibit the activity of monoacylglycerol lipase (MGL), the enzyme that hydrolyzes and deactivates the cannabionoid receptor ligand 2-Arachidonoyl-sn-glycerol (2-AG), in a reversible manner with high potency (IC50 = 93 nM).
      FormRed solid
      Intert gas (Yes/No) Packaged under inert gas
      CAS number1258-84-0
      Chemical formulaC₃₀H₄₀O₄
      Structure formulaStructure formula
      Purity≥95% by HPLC
      SolubilityDMSO (10 mg/ml) or Ethanol (2.5 mg/ml)
      Storage Protect from light
      +2°C to +8°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Toxicity Standard Handling
      ReferencesLu, Z., et al. 2010. Mol. Cancer 9, 112.
      King, A.R., et al. 2009. Chem. Biol. 16, 1045.
      Tiedemann, R.E., et al. 2009. Blood 113, 4027.
      Yang, H., et al. 2008. J. Cell. Biochem. 103, 234.
      Wu, C.C., et al. 2005. Mol. Cancer Ther. 4, 1277.